Suspended

PrimiBiotaIntestinal Microbiota Impact on Premature Infants' Immunity at Age 3

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
Study Aim

The study aims to observe how the intestinal microbiota affects the immune system of premature infants by the time they reach three years old.

What is being collected

Data Collection

Collected from today forward - Prospective
No DNA Sample
Who is being recruted

Urogenital Diseases+3

+ Female Urogenital Diseases and Pregnancy Complications

+ Obstetric Labor Complications

See all eligibility criteria
How is the trial designed

Cohort

Tracking disease incidence in order to identify risk factors and understand disease progression over time.
Observational
Study Start: May 2017
See protocol details

Summary

Principal SponsorCentre Hospitalier Universitaire de Nīmes
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: May 12, 2017

Actual date on which the first participant was enrolled.

This study focuses on understanding how the gut bacteria of premature infants develop and how it affects their immune system by the time they reach three years old. It explores how factors like the diversity and type of bacteria in their intestines evolve over time and its impact on their health. The study is particularly important for premature infants as they often face unique health challenges. By examining these changes, researchers hope to find better ways to support the development of a healthy immune system, potentially reducing the risk of infections, allergies, and inflammation in young children. Participants in this observational study involve premature infants whose gut bacteria will be monitored over time. Researchers will analyze samples to observe changes in bacterial diversity during the first six weeks of life and then again at ages one, two, and three years. They will also assess the children's immune system by looking at specific blood markers and their history of infections and allergic reactions. The study also considers how factors like the type of delivery, duration of breastfeeding, and antibiotic use in the neonatal period influence these changes. The goal is to determine if these early influences on gut bacteria can predict the direction of the immune system's development.

Official TitleInfluence of Intestinal Microbiota Implantation Parameters in the Neonatal Period in Premature Infants on Microbiota Profiles and Immune Orientation at 3 Years of Age
NCT02738411
Principal SponsorCentre Hospitalier Universitaire de Nīmes
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

130 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Cohort

These studies follow a group of individuals with common characteristics (such as a condition or birth year) over a specific period to study health outcomes or exposures.


Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsObstetric Labor ComplicationsObstetric Labor, PrematurePregnancy ComplicationsPremature Birth

Criteria

Inclusion Criteria: * The parents of the patient (or legal guardian if any) have been informed about the implementation of the study, its objectives, its constraints, and patient rights * The parents of the patient (or legal guardian if any) must have given their free and informed consent and signed the consent form * The patient must be affiliated with or beneficiary of a health insurance plan * Premature infants born at less than 33 weeks of gestation Exclusion Criteria: * The patient is participating in another interventional study (Excepted " Recherche du Portage de Clostridium butyricum et de Toxines de Clostridium chez les Prématurés Hospitalisés en Néonatologie afin de prédire la survenue d'Entérocolites Nécrosantes", RCB 2016-A00-529-42 ; " BetaDose Dose reduction of antenatal betamethasone given to prevent the neonatal complications associated with very preterm birth ", RCB 2016-001486-90. * It is not possible to correctly inform the parent (or legal guardian, if applicable) * A serious deformity or digestive malformation was diagnosed at birth * During the hospital stay in the neonatology department, the patient had a digestive disease requiring surgery (except necrotizing enterocolitis) * A transfer to another hospital is foreseen/predictable (eg, due to geographical distance)

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Study Objectives

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 3 locations

Suspended

CHRU de Montpellier - Hôpital Arnaud de Villeneuve

Montpellier, FranceOpen CHRU de Montpellier - Hôpital Arnaud de Villeneuve in Google Maps
Suspended

CHRU de Nîmes - Hôpital Universitaire Carémeau

Nîmes, France
Suspended

Réseau GRANDIR EN LANGUEDOC-ROUSILLON

Saint-Gély-du-Fesc, France
Suspended3 Study Centers